Johnson D L, Farrell F X, Barbone F P, McMahon F J, Tullai J, Hoey K, Livnah O, Wrighton N C, Middleton S A, Loughney D A, Stura E A, Dower W J, Mulcahy L S, Wilson I A, Jolliffe L K
R. W. Johnson Pharmaceutical Research Institute, Drug Discovery Research, Raritan, New Jersey 08869, USA.
Biochemistry. 1998 Mar 17;37(11):3699-710. doi: 10.1021/bi971956y.
To obtain information about the functional importance of amino acids required for effective erythropoietin (EPO) mimetic action, the conserved residues of a peptide mimetic of EPO, recently discovered by phage display, were subjected to an alanine replacement strategy. Further, to identify a minimal mimetic peptide sequence, a series of truncation peptides has been generated. One EPO mimetic peptide sequence, EMP1, was targeted and more than 25 derivatives of this sequence were evaluated for their ability to compete with [125I]EPO for receptor binding and for their ability to support the proliferation of two EPO-responsive cell lines. Two hydrophobic amino acids, Tyr4 and Trp13, appear essential for mimetic action, and aromatic residues appear to be important at these sites. These findings are consistent with the previously reported X-ray crystal structure of EMP1 complexed with the extracellular domain of the EPO receptor (EPO binding protein; EBP). In our efforts to define the structural elements required for EPO mimetic action, a 13 amino acid peptide was identified which possesses mimetic properties and contains a minimal agonist epitope. The ability of this peptide to effectively serve as a mimetic capable of the induction of EPO-responsive cell proliferation appears to reside within a single residue, equivalent to position Tyr4 of EMP1, when present in a sequence that includes the cyclic core peptide structure. Although these peptides are less potent than EPO, they should serve as an excellent starting point for the design of compounds with EPO mimetic activity.
为了获取关于有效促红细胞生成素(EPO)模拟作用所需氨基酸功能重要性的信息,对最近通过噬菌体展示发现的EPO模拟肽的保守残基采用了丙氨酸替代策略。此外,为了鉴定最小模拟肽序列,生成了一系列截短肽。靶向了一个EPO模拟肽序列EMP1,并评估了该序列的25种以上衍生物与[125I]EPO竞争受体结合的能力以及支持两种EPO反应性细胞系增殖的能力。两个疏水氨基酸Tyr4和Trp13对于模拟作用似乎至关重要,并且芳香族残基在这些位点似乎很重要。这些发现与先前报道的EMP1与EPO受体细胞外结构域(EPO结合蛋白;EBP)复合的X射线晶体结构一致。在我们确定EPO模拟作用所需结构元件的过程中,鉴定出了一种13个氨基酸的肽,它具有模拟特性并包含一个最小激动剂表位。当该肽存在于包含环状核心肽结构的序列中时,其有效充当能够诱导EPO反应性细胞增殖的模拟物的能力似乎取决于单个残基,等同于EMP1的Tyr4位置。尽管这些肽的效力不如EPO,但它们应作为设计具有EPO模拟活性化合物的良好起点。